Answers are grounded in this paper and cite their sources.
Our study aims to develop a genetic treatment strategy using antisense oligonucleotide treatment targeting the causal missense variant in Charcot-Marie-Tooth type 2E in an iPSC-derived motor neuron model system.
No takes yet. Share an insight, caveat, or question.
Medina et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: